USDTL Unveils New “bath Salts” Assay in Umbilical Cord</p>

DES PLAINES, Ill. (June 1, 2012) – United States Drug Testing Laboratories, Inc (USDTL), a reference laboratory specializing in alcohol and substances of abuse testing, released a new assay testing umbilical cord for newborn exposure in utero to Designer Stimulants/ Bath Salts on Friday, June 1, 2012. The CordStat® assay screens for the most common of designer stimulants known as “Bath Salts.”

Designer stimulants produce an euphoric high and have been described by the CDC as “a serious public threat.” These stimulants are packaged as bath salts, plant food or stain remover with labels that indicate “not for human consumption”. (CDC, 2011; Dargan et al, 2010; Dargan et al, 2011). Officials say the powdery substance mimics the effects of cocaine, ecstasy and LSD. These chemicals can cause hallucinations, paranoia, rapid heart rates, violent behavior and suicidal thoughts.

Healthcare workers are seeing neonatal abstinence syndrome (NAS) like symptoms similar to those seen in newborns exposed to the drugs listed above but cannot be attributed to opiates or other commonly screened for substances of abuse. Due in part to the lack of a widely-available, objective screen to identify newborns that have been exposed to designer stimulants, currently no specific research exists concerning the short-term or long-term harm caused by in utero exposure to designer stimulants. That said, the UK Teratology Information Service has warned that use of designer stimulants should be avoided during pregnancy (UKTIS, 2010).

CordStat® is an ideal clinical assay for healthcare practitioners concerned with monitoring newborns at high risk for having been exposed to Bath Salts/Designer Stimulants. The assay, which tests for 8 of the most common ingredients, can be ordered as an add-on test to one of our standard CordStat® 5-, 7-, 9-, 12- and 13-drug panels. To order, researchers and clinicians can contact Client Services at (800) 235-2367 or at clientservices@usdtl.com.

Established in 1991 as a specialty drug testing facility, USDTL quickly became a leader in the industry.USDTL has made significant breakthroughs by developing procedures to effectively use umbilical cord tissue and meconium specimens to diagnose alcohol misuse and substances of abuse. To find out more, please visit https://www.usdtl.com/.

Contact:
Bob Demaree, Clinical Projects Manager
bob.demaree@usdtl.com
(800) 235-2367

Back to view all blogs posts